VERA - Company ID 0001831828
Vera Therapeutics, Inc. trades as VERA and has a market capitalization of $3.04 B, making it the #1815 largest US-listed company by market value. This page tracks Vera Therapeutics, Inc. through 447 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Major company event | 8-K | 2026-05-26 |
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | Vera Therapeutics
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Vera Therapeutics
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | Vera Therapeutics
The largest companies sharing Vera Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Vera Therapeutics, Inc. (VERA) has a market capitalization of $3.04 B as of 2026-07-09, ranking #1815 among US-listed companies.
In its latest fiscal year Vera Therapeutics, Inc. reported a net loss of $299.62M.